Khosla Ventures AI portfolio in San Francisco

Everything needs food to survive and grow, including cancer. There is an entire dimension of human biology in metabolism that’s been too complex to leverage in the fight against cancer––until now.

• Series A
• 35 employees
• Founded 2019

Probably Genetic helps undiagnosed rare disease patients find answers to their symptoms in a matter of weeks. There are over 400 million people worldwide that have a rare disease — more than cancer and HIV patients combined. Half of those patients are currently undiagnosed and half of them are children, and it takes 5-7 years on average for these patients to get a diagnosis. With our system, patients can get answers in a matter of weeks. Our online Symptom Checker identifies rare disease patients using state-of-the-art machine learning models, gets them tested through our direct-to-consumer genetic testing service, and helps connect these patients to potentially life-saving treatments and advocacy communities. We partner with drug developers to offer sponsored testing programs that allow patients to access genetic testing for little to no cost.

• Series unknown
• 22 employees
• Founded 2018

Moonwalk Biosciences is pioneering novel therapeutics in adipose biology and tissue, driven by deep genetic and epigenetic evidence and insights. It utilizes its discovery platform to identify novel targets involved in obesity and cardiometabolic disease, and is advancing an early stage pipeline of therapeutic candidates.

• Series A
• 20 employees
• Founded 2022

Menten AI is pioneering generative AI to design cyclic peptide therapeutics for drug targets beyond the reach of small molecules and biologics. Our proprietary platform, MAUD 1.0, enables the rapid creation of macrocycles with drug-like properties such as oral bioavailability and cell permeability.We partner with top-10 pharma leaders (e.g., Bristol Myers Squibb) to accelerate preclinical discovery, and we are backed by world-class investors including Social Impact Capital, Uncork Capital, Khosla Ventures, and Y Combinator.

• Seed
• 19 employees
• Founded 2020

Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on its own internal pipeline. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster. We’re at a critical time in history where our need for new kinds of medicines is greater than any time in human memory. Fortunately, we can leverage advancing technology and scientific breakthroughs to accelerate discovery. New data, new algorithms, new compute platforms lift all of us, enable our work on the hardest of problems, empower us to invent and create, and ultimately save one billion lives. Join us: www.atomwise.com/careers

• Series D
• 15 employees
• Founded 2012